Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CRL | US
2.06
1.23%
Healthcare
Diagnostics & Research
30/06/2024
24/04/2026
169.80
169.10
171.63
167.20
Charles River Laboratories International Inc. a non-clinical contract research organization provides drug discovery non-clinical development and safety testing services in the United States Europe Canada the Asia Pacific and internationally. It operates through three segments: Research Models and Services (RMS) Discovery and Safety Assessment (DSA) and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates including research models genetically engineered models and services insourcing solutions and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets chemical compounds and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services such as toxicology pathology safety pharmacology bioanalysis drug metabolism and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs SPF chickens and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International Inc. was founded in 1947 and is headquartered in Wilmington Massachusetts.
View LessValue Stock (Price to Book < 3)
Price Below SMA10D
High Short-term Volatility
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
Declining Revenue (< 0%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
53.1%1 month
52.5%3 months
53.0%6 months
45.1%23.63
19.05
2.74
0.76
0.36
12.79
3.16
2.11
958.95M
8.77B
8.77B
-
16.60
-7.90
-3.20
12.60
2.94
4.94
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
24.58
Range1M
36.89
Range3M
78.45
Rel. volume
0.88
Price X volume
105.02M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| QIAGEN N.V | QGEN | Diagnostics & Research | 38.41 | 8.54B | 1.16% | 122.86 | 41.16% |
| ICON Public Limited Company | ICLR | Diagnostics & Research | 102.17 | 8.46B | -3.92% | 34.54 | 37.38% |
| Bio-Rad Laboratories Inc | BIO | Diagnostics & Research | 287.84 | 7.97B | 2.28% | n/a | 20.54% |
| Lantheus Holdings Inc | LNTH | Diagnostics & Research | 84.33 | 5.86B | 1.82% | 19.19 | 60.42% |
| Bruker Corporation | BRKR | Diagnostics & Research | 36.55 | 5.53B | 0.91% | 26.13 | 126.86% |
| Celcuity Inc | CELC | Diagnostics & Research | 121.03 | 4.48B | 6.58% | n/a | 54.62% |
| Sotera Health Company | SHC | Diagnostics & Research | 15.58 | 4.41B | 1.63% | 114.29 | 555.18% |
| RadNet Inc | RDNT | Diagnostics & Research | 57.63 | 4.26B | 2.11% | 378.67 | 195.04% |
| Senseonics Holdings Inc | SENS | Diagnostics & Research | 7.05 | 3.78B | 0.71% | n/a | 154.97% |
| Twist Bioscience Corporation | TWST | Diagnostics & Research | 60.94 | 3.57B | 3.55% | n/a | 17.75% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Dolby Laboratories Inc | DLB | Media - Diversified | 64.08 | 6.11B | 1.78% | 34.32 | 0.00% |
| FBIN | FBIN | Building Products & Equipment | 41.54 | 5.16B | 0.34% | 25.57 | 130.24% |
| Thor Industries Inc | THO | Recreational Vehicles | 79 | 4.18B | 0.24% | 23.44 | 27.88% |
| Cinemark Holdings Inc | CNK | Media - Diversified | 28.48 | 3.49B | -0.42% | 27.93 | 934.91% |
| VeriFone Systems Inc | PAY | Building Products & Equipment | 27.25 | 3.39B | 0.96% | 102.46 | 2.10% |
| Polaris Industries Inc | PII | Recreational Vehicles | 60.04 | 3.35B | 1.06% | 14.48 | 170.51% |
| LCI Industries | LCII | Recreational Vehicles | 120.01 | 3.06B | -0.45% | 25.82 | 77.66% |
| Harley-Davidson Inc | HOG | Recreational Vehicles | 23.11 | 3.04B | -1.15% | 7.33 | 218.58% |
| Pitney Bowes Inc | PBI | Building Products & Equipment | 15.58 | 2.80B | 1.37% | n/a | -571.93% |
| IMAX Corporation | IMAX | Media - Diversified | 36.45 | 1.92B | -0.44% | 54.26 | 110.44% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 12.79 | 12.67 | Par |
| Ent. to Revenue | 3.16 | 44.00 | Cheaper |
| PE Ratio | 23.63 | 40.09 | Cheaper |
| Price to Book | 2.74 | 77.50 | Cheaper |
| Dividend Yield | - | 1.18 | - |
| Std. Deviation (3M) | 53.04 | 59.59 | Par |
| Debt to Equity | 0.76 | -14.36 | Expensive |
| Debt to Assets | 0.36 | 0.34 | Par |
| Market Cap | 8.77B | 13.71B | Emerging |